Cat.No：GM-87971MAB
Product：Anti-PD1 hIgG1 Reference Antibody (Perbio)
Cat.No：GM-87971MAB
Product：Anti-PD1 hIgG1 Reference Antibody (Perbio)
GM-87971MAB-1mg / 1 mg
GM-87971MAB-5mg / 5 mg
GM-87971MAB-25mg / 5 mg * 5 vials
GM-87971MAB-50mg / 50 mg
GM-87971MAB-100mg / 50 mg * 2 vials
Expression System | CHO |
Aggregation | < 5% as determined by SEC-HPLC |
Purity | > 95% as determined by SDS-PAGE |
Species Reactivity | Human |
Clone | Peresolimab |
Source/Isotype | Monoclonal Human IgG1 (KDEL),Kappa |
Application | Flow Cytometry |
Specificity | Detects PD1 |
Gene | PD1 |
Other Names | CD279, PD-1, PDCD1, SLEB2, hPD-1, hPD-l, hSLE1 |
Gene ID | 6622 |
Background | Programmed cell death protein-1 (PD-1) is an inhibitory immune checkpoint primarily expressed by immune cells. In the tumor microenvironment, PD-1 binds to its ligands PD-L1 and PD-L2, inhibiting T cell activation and proliferation, which allows tumor cells to evade immune system surveillance. Peresolimab, a monoclonal antibody against PD-1(programmed death protein 1) , falls into the category of immune checkpoint inhibitors. It is mainly used in cancer therapy, by blocking the interaction between PD-1 and its ligands PD-L1 and PD-L2, enhance the body's immune system against tumor cells. |
Formulation | Phosphate-buffered solution, pH 7.2-7.4. |
Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
Cat.No：GM-87971MAB
Product：Anti-PD1 hIgG1 Reference Antibody (Perbio)
GM-87971MAB-1mg / 1 mg
GM-87971MAB-5mg / 5 mg
GM-87971MAB-25mg / 5 mg * 5 vials
GM-87971MAB-50mg / 50 mg
GM-87971MAB-100mg / 50 mg * 2 vials
Expression System | CHO |
Aggregation | < 5% as determined by SEC-HPLC |
Purity | > 95% as determined by SDS-PAGE |
Species Reactivity | Human |
Clone | Peresolimab |
Source/Isotype | Monoclonal Human IgG1 (KDEL),Kappa |
Application | Flow Cytometry |
Specificity | Detects PD1 |
Gene | PD1 |
Other Names | CD279, PD-1, PDCD1, SLEB2, hPD-1, hPD-l, hSLE1 |
Gene ID | 6622 |
Background | Programmed cell death protein-1 (PD-1) is an inhibitory immune checkpoint primarily expressed by immune cells. In the tumor microenvironment, PD-1 binds to its ligands PD-L1 and PD-L2, inhibiting T cell activation and proliferation, which allows tumor cells to evade immune system surveillance. Peresolimab, a monoclonal antibody against PD-1(programmed death protein 1) , falls into the category of immune checkpoint inhibitors. It is mainly used in cancer therapy, by blocking the interaction between PD-1 and its ligands PD-L1 and PD-L2, enhance the body's immune system against tumor cells. |
Formulation | Phosphate-buffered solution, pH 7.2-7.4. |
Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
